Moerman Rada V, Arends Suzanne, Meiners Petra M, Vissink Arjan, Spijkervet Frederik K L, Kroese Frans G M, Brouwer Elisabeth, Bootsma Hendrika
From the Departments of Rheumatology and Clinical Immunology and Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, the Netherlands.
R.V. Moerman, MD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; S. Arends, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; P.M. Meiners, MD, PhD, Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen; A. Vissink, MD, PhD, Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen; F.K. Spijkervet, MD, PhD, Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen; F.G. Kroese, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; E. Brouwer, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen; H. Bootsma, MD, PhD, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen.
J Rheumatol. 2017 Mar;44(3):292-296. doi: 10.3899/jrheum.160459. Epub 2017 Jan 15.
We used the 28-joint Disease Activity Score (DAS28) and the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) articular domain to assess the effect of rituximab (RTX) and abatacept (ABA) on articular involvement in primary Sjögren syndrome (pSS).
Patients with pSS treated with RTX (n = 18) or ABA (n = 13) and having a DAS28 erythrocyte sedimentation rate (ESR)/C-reactive protein (CRP) level ≥ 3.2 at baseline were selected. Generalized estimating equations were used to analyze the DAS28 and ESSDAI articular domain over time.
In the RTX group, DAS28-ESR/CRP decreased significantly up to 48 weeks. In the ABA group, DAS28-ESR/CRP decreased significantly up to 24 weeks. DAS28 correlated significantly with ESSDAI articular domain.
DAS28 is useful to evaluate the effect of biologicals on articular involvement in patients with pSS.
我们使用28个关节疾病活动评分（DAS28）和欧洲抗风湿病联盟干燥综合征疾病活动指数（ESSDAI）的关节领域来评估利妥昔单抗（RTX）和阿巴西普（ABA）对原发性干燥综合征（pSS）关节受累的影响。
选择基线时DAS28红细胞沉降率（ESR）/C反应蛋白（CRP）水平≥3.2且接受RTX治疗（n = 18）或ABA治疗（n = 13）的pSS患者。使用广义估计方程分析随时间变化的DAS28和ESSDAI关节领域。
在RTX组中，DAS28-ESR/CRP在48周内显著下降。在ABA组中，DAS28-ESR/CRP在24周内显著下降。DAS28与ESSDAI关节领域显著相关。
DAS28有助于评估生物制剂对pSS患者关节受累的影响。
